搜索结果
疾病ID:TCMBANKDI010968
疾病名:Carotid Stenosis
MeSH_Name:Nervous System Diseases; Cardiovascular Diseases
HPO_Name:Abnormality of the cardiovascular system
UMLS_Name:Disease or Syndrome
DO_Name:disease of anatomical entity
疾病类型:disease
DisGeNET_Link:C0007282
MeSH_Link:C10; C14
HPO_Link:HP:0001626
UMLS_Link:T047
DO_Link:DOID:7
HERB_ID:-
疾病对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
疾病对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
疾病对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE011380 | CLEC11A | CLECSF3; LSLCL; P47; SCGF | C-type lectin domain containing 11A |
| TCMBANKGE005143 | FCGR3B | CD16; CD16A; CD16b; FCG3; FCGR3; FCGR3A; FCR-10; FCRIII; FCRIIIb | Fc fragment of IgG receptor IIIb |
| TCMBANKGE010971 | FABP2 | FABPI; I-FABP | fatty acid binding protein 2 |
| TCMBANKGE003321 | F5 | FVL; PCCF; RPRGL1; THPH2 | coagulation factor V |
| TCMBANKGE010765 | HSPA2 | HSP70-2; HSP70-3 | heat shock protein family A (Hsp70) member 2 |
| TCMBANKGE000973 | EGF | HOMG4; URG | epidermal growth factor |
| TCMBANKGE000260 | APOB | FCHL2; FLDB; LDLCQ4; apoB-100; apoB-48 | apolipoprotein B |
| TCMBANKGE004586 | CSE1L | CAS; CSE1; XPO2 | chromosome segregation 1 like |
| TCMBANKGE000755 | PPIA | CYPA; CYPH; HEL-S-69p | peptidylprolyl isomerase A |
| TCMBANKGE000562 | IL18 | IGIF; IL-18; IL-1g; IL1F4 | interleukin 18 |
| TCMBANKGE012703 | LIPC | HDLCQ12; HL; HTGL; LIPH | lipase C, hepatic type |
| TCMBANKGE008534 | CNP | CNP1 | 2',3'-cyclic nucleotide 3' phosphodiesterase |
| TCMBANKGE008584 | CTNND1 | BCDS2; CAS; CTNND; P120CAS; P120CTN; p120; p120(CAS); p120(CTN) | catenin delta 1 |
| TCMBANKGE013299 | F3 | CD142; TF; TFA | coagulation factor III, tissue factor |
| TCMBANKGE006374 | RARRES2 | HP10433; TIG2 | retinoic acid receptor responder 2 |
| TCMBANKGE000395 | CXCL9 | CMK; Humig; MIG; SCYB9; crg-10 | C-X-C motif chemokine ligand 9 |
| TCMBANKGE000135 | CXCR4 | CD184; D2S201E; FB22; HM89; HSY3RR; LAP-3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPYY3R; WHIM; WHIMS | C-X-C motif chemokine receptor 4 |
| TCMBANKGE006489 | P2RY1 | P2Y1; SARCC | purinergic receptor P2Y1 |
| TCMBANKGE004283 | FBN2 | CCA; DA9; EOMD | fibrillin 2 |
| TCMBANKGE008857 | LPL | HDLCQ11; LIPD | lipoprotein lipase |
| TCMBANKGE000230 | ADIPOQ | ACDC; ACRP30; ADIPQTL1; ADPN; APM-1; APM1; GBP28 | adiponectin, C1Q and collagen domain containing |
| TCMBANKGE004687 | TREM1 | CD354; TREM-1 | triggering receptor expressed on myeloid cells 1 |
| TCMBANKGE013885 | PLA2G7 | LDL-PLA2; LP-PLA2; PAFAD; PAFAH | phospholipase A2 group VII |
| TCMBANKGE000882 | SERPINE1 | PAI; PAI-1; PAI1; PLANH1 | serpin family E member 1 |
| TCMBANKGE006061 | THBD | AHUS6; BDCA3; CD141; THPH12; THRM; TM | thrombomodulin |
| TCMBANKGE013197 | FCGR3A | CD16; CD16A; FCG3; FCGR3; FCGRIII; FCR-10; FCRIII; FCRIIIA; IGFR3; IMD20 | Fc fragment of IgG receptor IIIa |
| TCMBANKGE001034 | TLR2 | CD282; TIL4 | toll like receptor 2 |
| TCMBANKGE006352 | PROC | APC; PC; PROC1; THPH3; THPH4 | protein C, inactivator of coagulation factors Va and VIIIa |
| TCMBANKGE000161 | ADAMTS4 | ADAMTS-2; ADAMTS-4; ADMP-1 | ADAM metallopeptidase with thrombospondin type 1 motif 4 |
| TCMBANKGE000589 | CD68 | GP110; LAMP4; SCARD1 | CD68 molecule |
| TCMBANKGE007141 | MTHFR | - | methylenetetrahydrofolate reductase |
| TCMBANKGE000929 | MIR145 | MIRN145; miR-145; miRNA145 | microRNA 145 |
| TCMBANKGE000243 | LMNA | CDCD1; CDDC; CMD1A; CMT2B1; EMD2; FPL; FPLD; FPLD2; HGPS; IDC; LDP1; LFP; LGMD1B; LMN1; LMNC; LMNL1; MADA; PRO1 | lamin A/C |
| TCMBANKGE001037 | MMP2 | CLG4; CLG4A; MMP-2; MMP-II; MONA; TBE-1 | matrix metallopeptidase 2 |
| TCMBANKGE013747 | ADAM22 | ADAM 22; EIEE61; MDC2 | ADAM metallopeptidase domain 22 |
| TCMBANKGE000901 | ANGPT1 | AGP1; AGPT; ANG1 | angiopoietin 1 |
| TCMBANKGE009570 | LPA | AK38; APOA; LP | lipoprotein(a) |
| TCMBANKGE000271 | APOE | AD2; APO-E; ApoE4; LDLCQ5; LPG | apolipoprotein E |
| TCMBANKGE013582 | SOD3 | EC-SOD | superoxide dismutase 3 |
| TCMBANKGE006565 | NPY | PYY4 | neuropeptide Y |
| TCMBANKGE000867 | ITGB3 | BDPLT16; BDPLT2; CD61; GP3A; GPIIIa; GT | integrin subunit beta 3 |
| TCMBANKGE000746 | HSPA1A | HEL-S-103; HSP70-1; HSP70-1A; HSP70-2; HSP70.1; HSP70.2; HSP70I; HSP72; HSPA1 | heat shock protein family A (Hsp70) member 1A |
| TCMBANKGE000127 | MFN2 | CMT2A; CMT2A2; CMT2A2A; CMT2A2B; CPRP1; HMSN6A; HSG; MARF | mitofusin 2 |
| TCMBANKGE001126 | NFE2L2 | HEBP1; IMDDHH; NRF2; Nrf-2 | nuclear factor, erythroid 2 like 2 |
| TCMBANKGE010442 | SETD2 | HBP231; HIF-1; HIP-1; HSPC069; HYPB; KMT3A; LLS; SET2; p231HBP | SET domain containing 2, histone lysine methyltransferase |
| TCMBANKGE014640 | TIMP4 | TIMP-4 | TIMP metallopeptidase inhibitor 4 |
| TCMBANKGE000792 | FASLG | ALPS1B; APT1LG1; APTL; CD178; CD95-L; CD95L; FASL; TNFSF6; TNLG1A | Fas ligand |
| TCMBANKGE012295 | SLC39A2 | 6A1; ETI-1; ZIP-2; ZIP2 | solute carrier family 39 member 2 |
| TCMBANKGE000479 | TIMP1 | CLGI; EPA; EPO; HCI; TIMP; TIMP-1 | TIMP metallopeptidase inhibitor 1 |
| TCMBANKGE000563 | CLU | AAG4; APO-J; APOJ; CLI; CLU1; CLU2; KUB1; NA1/NA2; SGP-2; SGP2; SP-40; TRPM-2; TRPM2 | clusterin |
| TCMBANKGE001097 | HIF1A | HIF-1-alpha; HIF-1A; HIF-1alpha; HIF1; HIF1-ALPHA; MOP1; PASD8; bHLHe78 | hypoxia inducible factor 1 subunit alpha |
| TCMBANKGE006351 | TLN1 | ILWEQ; TLN; talin-1 | talin 1 |
| TCMBANKGE000513 | CYP2C19 | CPCJ; CYP2C; CYPIIC17; CYPIIC19; P450C2C; P450IIC19 | cytochrome P450 family 2 subfamily C member 19 |
| TCMBANKGE010121 | PPIG | CARS-Cyp; CYP; SCAF10; SRCyp | peptidylprolyl isomerase G |
| TCMBANKGE008113 | CD74 | DHLAG; HLADG; II; Ia-GAMMA; p33 | CD74 molecule |
| TCMBANKGE004351 | PADI4 | PAD; PAD4; PADI5; PDI4; PDI5 | peptidyl arginine deiminase 4 |
| TCMBANKGE012551 | DHX40 | ARG147; DDX40; PAD | DEAH-box helicase 40 |
| TCMBANKGE001158 | LEP | LEPD; OB; OBS | leptin |
| TCMBANKGE000681 | TNFRSF11B | OCIF; OPG; PDB5; TR1 | TNF receptor superfamily member 11b |
| TCMBANKGE005742 | LGMN | AEP; LGMN1; PRSC1 | legumain |
| TCMBANKGE001697 | MMP1 | CLG; CLGN | matrix metallopeptidase 1 |
| TCMBANKGE000787 | VCAM1 | CD106; INCAM-100 | vascular cell adhesion molecule 1 |
| TCMBANKGE000823 | GABPA | E4TF1-60; E4TF1A; NFT2; NRF2; NRF2A; RCH04A07 | GA binding protein transcription factor subunit alpha |
| TCMBANKGE000741 | HSPA1B | HSP70-1; HSP70-1B; HSP70-2; HSP70.1; HSP70.2; HSP72; HSPA1; HSX70 | heat shock protein family A (Hsp70) member 1B |
| TCMBANKGE008481 | VWF | F8VWF; VWD | von Willebrand factor |
| TCMBANKGE014208 | CAD | CDG1Z; EIEE50; GATD4 | carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase |
| TCMBANKGE000109 | ACTB | BRWS1; PS1TP5BP1 | actin beta |
| TCMBANKGE006553 | PON1 | ESA; MVCD5; PON | paraoxonase 1 |
| TCMBANKGE001144 | CD14 | - | CD14 molecule |
| TCMBANKGE014557 | ANXA1 | ANX1; LPC1 | annexin A1 |
| TCMBANKGE006724 | REN | HNFJ2 | renin |
| TCMBANKGE001273 | PROCR | CCCA; CCD41; EPCR | protein C receptor |
| TCMBANKGE000885 | SPP1 | BNSP; BSPI; ETA-1; OPN | secreted phosphoprotein 1 |
| TCMBANKGE000219 | CCR5 | CC-CKR-5; CCCKR5; CCR-5; CD195; CKR-5; CKR5; CMKBR5; IDDM22 | C-C motif chemokine receptor 5 |
| TCMBANKGE001125 | IGF1 | IGF; IGF-I; IGFI; MGF | insulin like growth factor 1 |
| TCMBANKGE005557 | LCN2 | 24p3; MSFI; NGAL; p25 | lipocalin 2 |
| TCMBANKGE000419 | SMS | MRSR; SPMSY; SRS; SpS | spermine synthase |
| TCMBANKGE007998 | TSPO | BPBS; BZRP; DBI; IBP; MBR; PBR; PBS; PKBS; PTBR; mDRC; pk18 | translocator protein |
| TCMBANKGE014176 | ANGPT2 | AGPT2; ANG2 | angiopoietin 2 |
| TCMBANKGE007503 | HABP2 | FSAP; HABP; HGFAL; NMTC5; PHBP | hyaluronan binding protein 2 |
| TCMBANKGE001096 | TLR4 | ARMD10; CD284; TLR-4; TOLL | toll like receptor 4 |
| TCMBANKGE002913 | ETS1 | ETS-1; EWSR2; c-ets-1; p54 | ETS proto-oncogene 1, transcription factor |
| TCMBANKGE004635 | MDC1 | NFBD1 | mediator of DNA damage checkpoint 1 |
| TCMBANKGE000828 | TREM2 | PLOSL2; TREM-2; Trem2a; Trem2b; Trem2c | triggering receptor expressed on myeloid cells 2 |
| TCMBANKGE000716 | MT2A | MT-2; MT-II; MT2 | metallothionein 2A |
| TCMBANKGE006425 | SLC26A4 | DFNB4; EVA; PDS; TDH2B | solute carrier family 26 member 4 |
| TCMBANKGE006611 | ST8SIA4 | PST; PST1; SIAT8D; ST8SIA-IV | ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 |
| TCMBANKGE000244 | ZMPSTE24 | FACE-1; FACE1; HGPS; PRO1; STE24; Ste24p | zinc metallopeptidase STE24 |
| TCMBANKGE002676 | SORL1 | C11orf32; LR11; LRP9; SORLA; SorLA-1; gp250 | sortilin related receptor 1 |
| TCMBANKGE000330 | HMOX1 | HMOX1D; HO-1; HSP32; bK286B10 | heme oxygenase 1 |
| TCMBANKGE008183 | ACE | ACE1; CD143; DCP; DCP1 | angiotensin I converting enzyme |
| TCMBANKGE001054 | ABCA1 | ABC-1; ABC1; CERP; HDLCQTL13; HDLDT1; HPALP1; TGD | ATP binding cassette subfamily A member 1 |
| TCMBANKGE010787 | CHIT1 | CHI3; CHIT; CHITD | chitinase 1 |
| TCMBANKGE013184 | HP | BP; HP2ALPHA2; HPA1S | haptoglobin |
| TCMBANKGE004683 | BCAR1 | CAS; CAS1; CASS1; CRKAS; P130Cas | BCAR1 scaffold protein, Cas family member |
| TCMBANKGE006961 | F2 | PT; RPRGL2; THPH1 | coagulation factor II, thrombin |
| TCMBANKGE012224 | VDR | NR1I1; PPP1R163 | vitamin D receptor |
| TCMBANKGE000389 | MMP3 | CHDS6; MMP-3; SL-1; STMY; STMY1; STR1 | matrix metallopeptidase 3 |
| TCMBANKGE011695 | PCYT1A | CCTA; CT; CTA; CTPCT; PCYT1; SMDCRD | phosphate cytidylyltransferase 1, choline, alpha |
| TCMBANKGE000783 | PCSK9 | FH3; FHCL3; HCHOLA3; LDLCQ1; NARC-1; NARC1; PC9 | proprotein convertase subtilisin/kexin type 9 |
| TCMBANKGE000829 | FABP4 | A-FABP; AFABP; ALBP; HEL-S-104; aP2 | fatty acid binding protein 4 |
| TCMBANKGE013151 | TM7SF2 | ANG1; C14SR; DHCR14A; NET47 | transmembrane 7 superfamily member 2 |
| TCMBANKGE013703 | AGR2 | AG-2; AG2; GOB-4; HAG-2; HEL-S-116; HPC8; PDIA17; XAG-2 | anterior gradient 2, protein disulphide isomerase family member |
| TCMBANKGE000315 | IL4 | BCGF-1; BCGF1; BSF-1; BSF1; IL-4 | interleukin 4 |
滇IICP备16009434号-1 |
Dai SX Lab